Drug R&D Models Will Change Drastically By 2020, PwC Report Predicts
Executive Summary
The pharmaceutical industry is about to face a world in which successful companies no longer focus on blockbusters, drugs are approved in stages for an ever widening patient population, and large sales teams have been replaced by advisers, according to a report by PricewaterhouseCooperYou may also be interested in...
Lilly Sings A New Tune: Chorus Unit Brings High Efficiency Note To Early R&D
Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization
PDUFA Provides Opportunity For Conditional Approvals, Consumer Groups Say
Consumer groups are advocating the creation of a "conditional" approval authority for FDA through the reauthorization of the Prescription Drug User Fee Act
Pharma Industry Broadens Its Approach To Expanded Access
Novartis co-leads industry forum on preapproval access that aims to share best practices and engage patient groups; Janssen is launching three pilots to leverage collection of preapproval access data.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: